Insights into Treatment Patterns in the Routine Care of Patients Diagnosed with Metastatic Castration-Resistant Prostate Cancer in Germany After the Introduction of New Therapies
Insights into Treatment Patterns in the Routine Care of Patients Diagnosed with Metastatic Castration-Resistant Prostate Cancer in Germany After the Introduction of New Therapies
Download Citation in txt
Download Citation in bib
Download Citation in ris
Author Info
Nahila Justo Bernd Schweikert Andreas Simon A. Reginald Waldeck Michael Meinhardt Yves-René Samel Peter J. Goebell
Corresponding Author
Nahila JustoDepartment of Neurobiology, Care Sciences and Society at Karolinska Institute, Stockholm, Sweden
A B S T R A C T
Background: Clinical treatment guidelines for metastatic castration-resistant prostate cancer (mCRPC) predominantly rely on the evidence from clinical trials, which frequently apply restrictive eligibility criteria resulting in selected patient populations. Therefore, real world treatment pattern may deviate from recommendations. We aimed to describe treatment patterns including sequencing and treatment duration of patients diagnosed with mCRPC in Germany, by characterizing the demographic and clinical characteristics of patients. Methods: A large German claims database was used to identify males who were diagnosed and treated for mCRPC (ICD-10-GM code C61) between January 2013 and December 2015. Patients were required to be continuously enrolled 12 months before initiation of treatment with abiraterone, cabazitaxel, docetaxel, or enzalutamide. Study endpoints included lines of therapy, treatment duration and treatment sequencing. Treatment duration was calculated via Kaplan-Meier estimates. Results: There were n=447 patients meeting all inclusion criteria in the database. Mean age (±SD) was 72.9 (±8.8) years, mean Charlson comorbidity index was 8.1, there were on average 1.9 hospitalizations within the 12 months before the index, and 70% of patients presented with bone metastasis. Overall, abiraterone was the most commonly prescribed treatment across lines of therapy while cabazitaxel, was the least utilized therapy. The longest treatment duration was seen in abiraterone patients (median duration of 8.3 months in first and 7.4 months in second line). Switches between abiraterone and docetaxel in first and second line were common. Among the 447 patients more than 70 different pathways were identified. Conclusion: There was a significant variability in treatment pathways pointing to a highly individualized treatment approach in spite of detailed treatment algorithms. Even in third line, systemic therapies were still being prescribed. Furthermore, this study showed that routine-care data are a valuable source to assess the actual treatment pathways on a cohort but also on an individual level.
Article Info
Article Type
Research ArticlePublication history
Received: Sat 22, Aug 2020Accepted: Mon 07, Sep 2020
Published: Mon 28, Sep 2020
Copyright
© 2023 Nahila Justo. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.DOI: 10.31487/j.COR.2020.09.04